Welcome to our dedicated page for Biogen SEC filings (Ticker: BIIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biogen’s neuroscience pipeline stretches from multiple-sclerosis blockbusters to cutting-edge Alzheimer’s candidates, and the disclosures that follow are equally dense. If you’ve tried to spot pipeline milestones, patent cliffs, or R&D spend buried inside a 200-page filing, you know the challenge. Stock Titan turns that complexity into clarity by delivering Biogen SEC filings explained simply, in real time.
Our AI-powered summaries break down each Biogen annual report 10-K simplified, flagging segment revenue, drug concentration risk, and collaboration economics. Dig into a Biogen quarterly earnings report 10-Q filing without paging through footnotes—the platform highlights inventory swings, clinical-trial costs, and cash burn in seconds. Material updates like FDA decisions arrive as Biogen 8-K material events explained, so you never miss a catalyst.
The dashboard also tracks Biogen insider trading Form 4 transactions. Receive Biogen Form 4 insider transactions real-time to monitor Biogen executive stock transactions Form 4 before market open. Curious about leadership pay? The Biogen proxy statement executive compensation section is distilled into an easy-to-scan table. Whether you’re stress-testing valuation models or searching “How to read Biogen’s 10-K annual report?�, our AI delivers Biogen earnings report filing analysis that answers what professionals actually ask.
- Set keyword alerts for Leqembi, Spinraza, or biosimilar launches
- Compare quarter-over-quarter R&D trends instantly
- Export footnote-level data for financial models
Start understanding Biogen SEC documents with AI and spend minutes—not hours—finding what drives BIIB.
Biogen held its 2025 Annual Meeting of Stockholders on June 17, 2025, with three key matters put to vote. All eleven nominated directors were successfully elected to serve one-year terms until the 2026 annual meeting, with notable strong support for Lloyd Minor, Menelas Pangalos, and Monish Patolawala, each receiving over 114 million votes in favor.
Key voting outcomes include:
- Independent Auditor Appointment: PricewaterhouseCoopers LLP was ratified as the independent auditor for FY2025 with strong support (120,065,433 votes in favor)
- Say-on-Pay Vote: The executive compensation package was approved, though with more divided support - 78.5 million votes in favor versus 37.1 million against
The relatively split vote on executive compensation (67.8% approval) suggests some shareholder concerns about leadership remuneration. The high broker non-votes (10.2 million) across most items indicate significant holdings by institutional investors who did not provide voting instructions.
Form 4 overview: On 06/17/2025 Biogen (BIIB) director Menelas N. Pangalos received 2,370 restricted stock units (RSUs) at no cost. The units convert to common stock on the earlier of the company’s next annual meeting or 06/17/2026. After the award, the director beneficially owns 2,370 BIIB shares directly.
No shares were sold or disposed of; the filing reflects standard director compensation. Given Biogen’s large share count, the issuance is immaterial to dilution or valuation and therefore neutral for investors.
Biogen Inc. (BIIB) � Form 4 insider transaction
Independent director Dr. Lloyd Minor reported the acquisition of 2,370 shares of Biogen common stock on 17-Jun-2025. The transaction code “A� indicates that the shares were awarded rather than purchased on the open market; the reported price is $0, consistent with a restricted stock or director equity grant. Following the grant, Dr. Minor’s total direct ownership stands at 2,370 shares. No derivative securities were involved, and there were no dispositions.
The filing is routine director compensation disclosure and does not reveal any change in strategy, operations, or financial condition. However, fresh equity ownership marginally strengthens alignment between the director and shareholder interests.
Form 4 overview: On 06/17/2025, Biogen Inc. (BIIB) director Monish D. Patolawala reported the acquisition of 2,370 shares of common stock at a stated price of $0.00, suggesting a share grant or similar equity award. Following the transaction, Mr. Patolawala now beneficially owns 3,710 shares, held directly.
The filing contains no derivative security activity, sales, or monetary purchase and therefore does not indicate cash outlay or immediate market transactions. While the increase in personal holdings modestly aligns the director’s interests with shareholders, the size of the transaction is relatively small against Biogen’s roughly $33 billion market capitalization, implying limited near-term market impact.
Biogen Inc. (BIIB) � Form 4 insider filing
Director Jesus B. Mantas reported one transaction dated 06/17/2025. The filing shows an "A" transaction code (acquisition) for 2,370 shares of Biogen common stock at a stated price of $0.00, indicating a stock award or grant. After this transaction, the director’s direct beneficial ownership increases to 9,758 shares. No derivative security transactions were reported, and there are no sales or dispositions disclosed in the filing.
The form was signed by an attorney-in-fact on 06/18/2025. No other insiders or joint filers are involved, and there is no indication that the reporting person is no longer subject to Section 16.
Biogen Inc. (BIIB) has filed a Form 4 indicating that director William A. Hawkins acquired 2,370 shares of the company’s common stock on 06/17/2025. The transaction is coded “A� (acquisition) and carries a reported price of $0, suggesting the shares were granted rather than purchased on the open market. Following the transaction, Hawkins� direct beneficial ownership stands at 8,860 shares.
The filing confirms Hawkins� role as a director and notes the document was signed on 06/18/2025 by attorney-in-fact Wendell Taylor. No derivative security activity or additional transactions were reported.
Biogen Director Maria C. Freire reported the acquisition of 2,370 shares of Common Stock on June 17, 2025. The shares were acquired at $0 per share, suggesting this was likely a stock grant as part of director compensation.
Following this transaction, Freire now beneficially owns a total of 6,815 shares directly. The filing indicates this was a direct ownership transaction, with no indirect holdings reported. The Form 4 was signed by Wendell Taylor as attorney-in-fact for Dr. Freire on June 18, 2025.
This insider transaction represents a notable increase in Freire's equity stake in Biogen, demonstrating continued alignment between director and shareholder interests. No derivative securities were involved in this transaction.
Biogen Inc. (BIIB) � Form 4 insider transaction
Director Eric K. Rowinsky reported the acquisition of 2,370 shares of Biogen common stock on 06/17/2025. The filing lists the transaction code “A,� indicating the shares were acquired rather than sold; the stated price is $0.00, suggesting a board-related equity grant or similar stock-based award. Following the transaction, Rowinsky’s direct beneficial ownership increased to 24,339 shares, up from 21,969 shares—an increase of roughly 11%.
No derivative securities were reported, and there were no dispositions. The filing was signed on 06/18/2025 by an attorney-in-fact.
From an investment perspective, the event is routine and low-impact: it reflects standard director compensation and modestly tightens alignment between the board member and shareholders without affecting Biogen’s capital structure or cash flows.
Form 4 snapshot: Biogen Inc. (BIIB) director Stephen A. Sherwin reported the acquisition of 2,370 shares of common stock on 06/17/2025. The transaction price is recorded as $0.00, indicating a grant or award rather than an open-market purchase. Following the transaction, Sherwin’s direct beneficial ownership increased to 13,688 shares.
No derivative securities were reported, and there were no dispositions. The filing was signed on 06/18/2025 by attorney-in-fact Wendell Taylor.
SEC Form 4 filed on 06/18/2025 reveals that Biogen Inc. (BIIB) director Susan K. Langer acquired 2,370 shares of common stock on 06/17/2025. The transaction is coded “A,� indicating an acquisition, and carries a stated price of $0 per share, characteristic of a director equity grant rather than an open-market purchase. Following the award, Langer’s direct beneficial ownership rises to roughly 5,129 shares. No derivative security activity or additional transactions were reported. The filing was signed by attorney-in-fact Wendell Taylor on behalf of the director. No other material changes or footnotes accompany the filing.
FAQ
What is the current stock price of Biogen (BIIB)?
What is the market cap of Biogen (BIIB)?
What is the core mission of Biogen Inc?
Which therapeutic areas does Biogen primarily target?
How does Biogen generate its revenue?
What role do strategic collaborations play for Biogen?
How is Biogen positioned within the competitive biotechnology sector?
What measures does Biogen take to ensure high quality and scientific rigor?
